Transferrin receptor (TfR)-lytic hybrid peptide

General Information


DCTPep ID  DCTPep00313

Peptide Name   Transferrin receptor (TfR)-lytic hybrid peptide

Sequence  THRPPMWSPVWPGGGKLlLKlLkkLLKlLKKK

Sequence Length  32

UniProt ID  Not available

PubChem CID  Not available

Origin  Transferrin receptor (TfR)

Type  Synthetic peptide

Classification

  

ACP Tumor active peptide Cancer targeted peptides



Activity Information


Cell Line Disease Activity Assay Testing Time Literature
T-47D Invasive breast carcinoma of no special type IC50=4.0 µM WST-1 assay 72 h 1
BT-20 Invasive breast carcinoma of no special type IC50=4.8 µM WST-1 assay 72 h 1
T-47D Invasive breast carcinoma of no special type IC50=4.8μM WST-8 assay 72h Patent
SK-BR-3 Breast adenocarcinoma IC50=5.3μM WST-8 assay 72h Patent
LNCaP Prostate carcinoma IC50=6.2 µM WST-1 assay 72 h 1
LNCaP Prostate carcinoma IC50=6.2μM WST-8 assay 72h Patent
SF295 Glioblastoma IC50=6.3 µM WST-1 assay 72 h 1
COLO 587 Colon adenocarcinoma IC50=6.4 µM WST-1 assay 72 h 1
SK-BR-3 Breast adenocarcinoma IC50=6.5 µM WST-1 assay 72 h 1
MDA-MB-231 Breast adenocarcinoma IC50=6.7μM WST-8 assay 72h Patent
U251 Astrocytoma IC50=6.8μM WST-8 assay 72h Patent
COLO 587 Colon adenocarcinoma IC50=6.9μM WST-8 assay 72h Patent
U-251MG Astrocytoma IC50=7.0 µM WST-1 assay 72 h 1
MDA-MB-231 Breast adenocarcinoma IC50=7.8 µM WST-1 assay 72 h 1
SN19 Glioblastoma IC50=7.8 µM WST-1 assay 72 h 1
SN19 Glioblastoma IC50=8.2μM WST-8 assay 72h Patent
HuCC-T1 Intrahepatic cholangiocarcinoma; Cholangiocarcinoma IC50=8.3 µM WST-1 assay 72 h 1
BT-474 Invasive breast carcinoma of no special type IC50=8.8 µM WST-1 assay 72 h 1
ZR-75-1 Invasive breast carcinoma of no special type IC50=9.3 µM WST-1 assay 72 h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  MRC-5: IC50>20μM; HC cell: IC50>20μM; PE cell: IC50>20μM

Target  Transferrin receptor

Affinity  Not available

Mechanism  Lytic peptide containing cationic-rich amino acids components that disintegrates the cell membrane for the cancer cell killing



Structure Information


PDB ID  Not available

Predicted Structure  Not available

(Please note that there is the predicted structure, predicted by AlphaFold)

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  l=D-Leucine; k=D-Lysine

Chiral  Mix



Physicochemical Information


Formula  Not Applicable

Absent amino acids  Not Applicable

Theoretical pI  Not Applicable

Acidic residues  Not Applicable

Basic residues  Not Applicable

Polar residues  Not Applicable

Molecular weight (Average)  Not Applicable

Molecular weight (Monoisotopic)  Not Applicable

Common amino acids  Not Applicable

Net charge  Not Applicable

Instability index (II)  Not Applicable

Aliphatic index  Not Applicable

Grand average of hydropathicity (GRAVY)  Not Applicable

Half Life 
  Not Applicable

Extinction coefficients 
  Not Applicable

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 21849092

Title  A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells

Doi 10.1186/1471-2407-11-359

Year  2011

Patent

Patent ID US 2011/0319336 A1

Patent Title  Selective anticancer chimeric peptide.

Other Iinformation  Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status: Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013

Other Published ID  CN102238965A  EP2370107A2  WO2010064207A2  WO2010064207A3 




DCTPep is developed by Dr.Zheng's team.